Administrative Core

总结/摘要 我们提出的P01题为发现和利用神经母细胞瘤（NB）治疗机制 抵抗是一种多学科和多机构的持续攻击，对未得到满足的改善需求进行攻击。 对患有这种疾病的高危儿童的影响。每一个国家都提出了雄心勃勃的目标， 项目旨在发现对标准和非标准治疗的新生和获得性治疗耐药性的基本机制， 作为新兴疗法，该计划需要有经验的领导来确定优先事项， 推动并交付符合既定里程碑的成果。因此，核心A将提供科学的、预算的 和行政领导，以及方案基础设施，以实现的翻译使命， 拟议的调查。在世界知名科学顾问委员会的指导下，核心A将 监督为NB儿童开发新一代合理设计的疗法， 有望最终提高治愈率，同时降低短期和长期毒性。

SUMMARY/ABSTRACT Our proposed P01 entitled Discovering and Exploiting Mechanisms of Neuroblastoma (NB) Therapy Resistance is a multi-disciplinary and multi-institutional sustained assault on the unmet need of improving outcomes for children with the high-risk form of the disease. With the ambitious goals articulated in each Project to discover fundamental mechanisms of de novo and acquired therapy resistance to both standard and newly emerging therapies, the Program requires experienced leadership to define priorities, sustain momentum and deliver results that meet defined milestones. Thus, Core A will provide the scientific, budgetary and administrative leadership, as well as the programmatic infrastructure to achieve the translational mission of the proposed investigation. With the guidance of a world-renowned scientific advisory board, Core A will oversee the development of a new generation of rationally designed therapies for children with NB that we expect to ultimately improve cure rates, while simultaneously reducing both short- and long-term toxicities.